A 3D-QSAR model for cannabinoid receptor (CB2) ligands derived from aligned pharmacophors
© Günther et al.; licensee BioMed Central Ltd. 2013
Published: 22 March 2013
Cannabinoid (CB) receptors have gained much attention as markers for various brain tumours and potential therapeutic targets of neuropathic pain and mood disorders. Two CB receptors have been cloned and described: CB1, predominantly expressed in the brain and CB2, primarily found in the peripheral system but also in brain. The CB2 receptor is suggested to be involved in various neurodegenerative diseases, such as Alzheimer's or Parkinson's disease . Early and non-invasive diagnosis and therapy monitoring of such diseases is desired. Positron-Emission-Tomography (PET) allows imaging of functional processes in living humans. For this, compounds with positron emitting labels like 18F are used. Due to the high sensitivity of PET, such radiotracers must bind to the target protein with high selectivity.
- Scotter EL, Abood ME, Glass M: The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease. Br J Pharmacol. 2010, 160: 480-498. 10.1111/j.1476-5381.2010.00735.x.View ArticleGoogle Scholar
- Asakawa N, Kobayashi S, Goto J, Hirayama N: AutoGPA: A novel 3D-QSAR method based on grid potential analysis and pharmacophore alignment. Poster presentation at 10th InCoB - 1st ISCB Asia Joint Conference (InCoB2011/ISCB-Asia 2011); Kuala Lumpur, MalaysiaGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.